A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Age 6-18 years, male or female;
Histologically confirmed classic Hodgkin lymphoma;
Newly diagnosed, previously untreated patients;
Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter >1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter >1.0 cm;
Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);
Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);
Patients with central nervous system (CNS) involvement by lymphoma;
Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;